Wiederschain
Dmitri Wiederschain, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20140178893 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 06-26-2014 |
20150037814 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 02-05-2015 |
Dmitri G. Wiederschain, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20090156491 | METHODS OF INHIBITING ANGIOGENESIS WITH FRAGMENTS AND HOMOLOGS OF TROPONIN SUBUNIT I - The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I. | 06-18-2009 |
Gherman Wiederschain, Roslindale, MA US
Patent application number | Description | Published |
---|---|---|
20130337482 | ASSAYS AND KITS TO DETERMINE GALACTOCEREBROSIDASE ACTIVITY ON SOLID SUPPORT - The present invention discloses compositions, methods, assays and kits which provide for rapid, high-throughput and sensitive assays useful for detecting the activity of galactocerebrosidase (GALC) in a test sample. The methods, assays and kits of the present invention provide useful diagnostic tools which may be used to identify subjects suspected of having an enzyme deficiency and to evaluate the efficacy of enzyme replacement therapy. | 12-19-2013 |